



SUPPLEMENTARY FIGURE 3

A



B



Supplementary Figure S3. Maximum change from baseline in the sum of target lesions and treatment duration (“other tumor types”, intrahepatic cholangiocarcinoma, glioblastoma).

Subjects with “other tumor types” (OTT), intrahepatic cholangiocarcinoma (ICC) and glioblastoma (GBM) treated in dose escalation and dose expansion were included in the analysis. BAY1436032 was administered BID at the doses indicated. Subjects who were still ongoing at the time of data cutoff (Nov 2018) are depicted with an asterisk; all of these subjects were off study as of August 2020.

A. Maximum change from baseline in the sum of target lesions in subjects with valid baseline and during-treatment tumor measurements. Measurements are as of the data cutoff date of Nov 2018.

B. The actual duration of treatment (in months) at the time of data cutoff is indicated for subjects who had a duration of treatment >6 months by that time.